Oncopeptides has been granted a patent for a novel lyophilized pharmaceutical preparation containing melphalan flufenamide and excipients like hydroxypropyl-ß-cyclodextrin. The preparation is directly soluble in water and is intended for cancer therapy. GlobalData’s report on Oncopeptides gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Oncopeptides AB - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Oncopeptides, Peptide pharmacophores was a key innovation area identified from patents. Oncopeptides's grant share as of February 2024 was 46%. Grant share is based on the ratio of number of grants to total number of patents.

Lyophilized pharmaceutical preparation for cancer therapy

Source: United States Patent and Trademark Office (USPTO). Credit: Oncopeptides AB

A recently granted patent (Publication Number: US11896668B2) discloses a lyophilized pharmaceutical preparation that is directly soluble in a physiologically acceptable aqueous solution. The formulation includes melphalan flufenamide or its pharmaceutically acceptable salt, along with hydroxypropyl-ß-cyclodextrin and/or sulfobutylether-ß-cyclodextrin. The amount of cyclodextrins present is in the range of 10-100% by weight of melphalan flufenamide, with the formulation containing less than 0.5% by weight of organic solvents. Additionally, the preparation may consist solely of hydroxypropyl-ß-cyclodextrin or sulfobutylether-ß-cyclodextrin as excipients, with trace amounts of an organic solvent.

Furthermore, the patent claims cover various compositions involving the lyophilized pharmaceutical preparation and a physiologically acceptable solution, such as a glucose solution. The formulations may include different percentages of cyclodextrins and melphalan flufenamide, with the presence of trace amounts of organic solvents. The patent also specifies variations where hydroxypropyl-ß-cyclodextrin or sulfobutylether-ß-cyclodextrin are the sole excipients in the lyophilized pharmaceutical preparation, emphasizing their role in the solubility and stability of the formulation. Overall, the patent highlights the unique characteristics of the lyophilized pharmaceutical preparation and its potential applications in the field of pharmaceuticals.

To know more about GlobalData’s detailed insights on Oncopeptides, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies